Subtype
WHO Grade 4 Glioma
CI-CAN-00007117Explore in graph →
535 active trials3 approved drugs58 evidence items
- NCIt
- C200758
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007117Explore in graph →
Clinical trials
1,854 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (302)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 |
| NCT05664243 | A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 4 | In8bio Inc.INDUSTRY | 1 | May 1, 2025 | clinicaltrials |
| NCT06221553 | Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG(CMD03DIPG) | recruiting | Phase 1 | 9 | Chulalongkorn UniversityOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT06690216 | Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors(PD-L1-PET) | enrolling by invitation | Phase 1 / Phase 2 | 100 | Man HuOTHER | 1 | Mar 30, 2025 | clinicaltrials |
| NCT05769660 | A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Temozolomide in Patients with Recurrent or Progressive Glioblastoma Multiforme (GBM) | recruiting | Phase 1 | 12 | BeyondBio Inc.INDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT04590664 | Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma | recruiting | Phase 1 / Phase 2 | 24 | Emory UniversityOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma(NANO-GBM) | active not recruiting | Phase 1 / Phase 2 | 66 | Centre Jean PerrinOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT06097975 | A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma(NEO-GLITIPNI) | recruiting | Phase 1 | 18 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT04758533 | Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy(AloCELYVIR) | active not recruiting | Phase 1 / Phase 2 | 13 | Hospital Infantil Universitario Niño Jesús, Madrid, SpainOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05561374 | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma | active not recruiting | Phase 1 | 16 | Oblato, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | recruiting | Phase 1 / Phase 2 | 30 | SignPath Pharma, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT06640582 | TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas(BAH2472) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT01985087 | A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70 | active not recruiting | Phase 1 / Phase 2 | 18 | University of LouisvilleOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT00102648 | Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with Temozolomide | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | enrolling by invitation | Phase 1 | 50 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | not yet recruiting | Phase 1 | 9 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 29, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06305910 | CD200AR-L and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent HGG and Newly Diagnosed DMG/DIPG in Children and Young Adults | recruiting | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05717699 | Oncolytic Virus Ad-TD-nsIL12 for Progressive Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05717712 | Oncolytic Virus Ad-TD-nsIL12 for Primary Pediatric Diffuse Intrinsic Pontine Glioma | recruiting | Phase 1 | 18 | Capital Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 25, 2025source: clinicaltrials